Clinical Observation of the Reduction of Anthracycline-induced Cardiotoxicity in Patients with Breast Cancer by Dexrazoxane Combined with Shenmai Injection
10.6039/j.issn.1001-0408.2015.32.35
- VernacularTitle:右丙亚胺联合参麦注射液用于蒽环类药物致乳腺癌患者心脏毒性的临床观察
- Author:
Wei YU
;
Zengqing GUO
;
Ruixiang XIE
;
Fang FAN
- Publication Type:Journal Article
- Keywords:
Dexrazoxane;
Shenmai injection;
Breast cancer;
Cardiotoxicity
- From:
China Pharmacy
2015;(32):4562-4564
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe therapeutic efficacy and safety of dexrazoxane combined with Shenmai injection in the treatment of anthracycline-induced cardiotoxicity in patients with breast cancer. METHODS:120 female breast cancer patients were randomly divided into group A,B,C and D with 30 cases in each group. Group A was given CAF chemotherapy plan(cyclophos-phamide 75 mg/m2+fluorouracil 500 mg/m2 + doxorubicin 60 mg/m2),ivgtt;group B was additionally given Shenmai injection 50 ml,qd,ivgtt,on the basis of CAF plan;group C was additionally given rapid intravenous of dexrazoxane 60 mg/m2 30 min before chemotherapy,on the basis of CAF;group D was additionally given constant dose of dexrazoxane combine with Shenmai injection on the basis of CAF plan. A treatment course lasted for 3 weeks,they were given 4 courses in total. The change of ECG,LVEF, cTnT and BNP and the incidence of bone marrow suppression were observed before and after chemotherapy. RESULTS:After treat-ment,the rate of abnormal ECG,LVEF value,cTnT value and BNP value of groups B,C and D were all decreased significant-ly,with statistical significance(P<0.05). Compared with group D,above index of groups B and C were decreased significantly, with statistical significance(P<0.05). The incidence of bone marrow suppression was in ascending order,group D
